Stability Starts With Strategy: MACI and Concomitant Strategies in the Patellofemoral Joint

Patellofemoral cartilage defects present unique challenges, and the right strategy makes all the difference. In this expert-led webinar, nationally recognized cartilage repair surgeons will walk through their real-world approach to treating patellofemoral joint pathology with MACI® and concomitant interventions. Featuring patient case presentations, clinical insights, and practical procedural pearls, designed to give you actionable takeaways you can apply in your own practice.

This program is sponsored by Vericel Corporation and is not eligible for CE credits. Speakers are paid consultants of Vericel Corporation. For US HCPs only.

INDICATION

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold

product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or

without bone involvement in adults.

Limitations of Use

• Effectiveness of MACI in joints other than the knee has not been established.

• Safety and effectiveness of MACI in patients over the age of 55 years have not been established.

IMPORTANT SAFETY INFORMATION

Contraindications: MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin,

other aminoglycosides, products of porcine or bovine origin; in patients with severe osteoarthritis of the knee,

inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders; in patients

who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a

concomitant procedure to prepare the knee for a MACI implant; or in patients unable to cooperate with a physicianprescribed

post-surgical rehabilitation program.

Warnings and Precautions:

• Malignancy: The risk of MACI in patients with malignancy in the area of cartilage biopsy or implant is

unknown. Expansion of malignant or dysplastic cells present in biopsy tissue during manufacture and

subsequent implantation may be possible.

• Transmissible infectious diseases: Because patients undergoing procedures associated with MACI are not

routinely tested for transmissible infectious diseases, cartilage biopsy and MACI implant may carry risk of

transmitting infectious diseases.

• Presurgical Comorbidities: Local inflammation or active infection in the bone, joint, and surrounding soft

tissue, meniscal pathology, cruciate ligament instability, and misalignment should be assessed and treated

prior to or concurrent with MACI implantation.

• Product Sterility: Final sterility test results are not available at the time of shipping.

Adverse Reactions: The most frequently occurring adverse reactions reported for MACI (≥5%) were arthralgia,

tendonitis, back pain, joint swelling, and joint effusion. Serious adverse reactions reported for MACI were

arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.

Specific Populations:

• Use of MACI in pediatric patients (younger than 18 years of age) or in patients over 65 years of age has not

been established.

• The MACI implant is not recommended during pregnancy. For implantations post-pregnancy, the safety of

breastfeeding to an infant has not been determined.

To report negative side effects, contact Vericel Corporation at 1-800-453-6948 or FDA at 1-800-FDA-1088 (1-800-

332-1088) or www.fda.gov/medwatch.

Please see Full Prescribing Information.

MACI®, Vericel®, and the Vericel logo are registered trademarks of Vericel Corporation. ©2026 Vericel Corporation. All rights reserved